FDA Inspection 1247808 — UCB Pharma S.A.
The FDA completed an inspection of UCB Pharma S.A. on Feb 1, 2024 in Braine-L'Alleud. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Feb 1, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Braine-L'Alleud (Belgium)
Additional Details
Mutual Recognition Agreement (MRA)